Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation
Lucy J Garvey, Nicola Pavese, Anil Ramlackhansingh, Emma Thomson, Joanna M Allsop, Marios Politis, Ranjababu Kulasegaram, Janice Main, David J Brooks, Simon D Taylor-Robinson, Alan Winston, Lucy J Garvey, Nicola Pavese, Anil Ramlackhansingh, Emma Thomson, Joanna M Allsop, Marios Politis, Ranjababu Kulasegaram, Janice Main, David J Brooks, Simon D Taylor-Robinson, Alan Winston
Abstract
Background: Microglial cell activation and cerebral function impairment are described in both chronic hepatitis C viral (HCV) and Human-Immune-Deficiency viral (HIV) infections. The aim of this study was to investigate the effect of acute HCV infection upon cerebral function and microglial cell activation in HIV-infected individuals.
Methods: A case-control study was conducted. Subjects with acute HCV and chronic HIV coinfection (aHCV) were compared to matched controls with chronic HIV monoinfection (HIVmono). aHCV was defined as a new positive plasma HCV RNA within 12 months of a negative RNA test. Subjects underwent neuro-cognitive testing (NCT), cerebral proton magnetic resonance spectroscopy ((1)H-MRS) and positron emission tomography (PET) using a (11)C-radiolabeled ligand (PK11195), which is highly specific for translocator protein 18 kDA receptors on activated microglial cells. Differences between cases and controls were assessed using linear regression modelling.
Results: Twenty-four aHCV cases completed NCT and (1)H-MRS, 8 underwent PET. Of 57 HIVmono controls completing NCT, 12 underwent (1)H-MRS and 8 PET. Subjects with aHCV demonstrated on NCT, significantly poorer executive function (mean (SD) error rate 26.50(17.87) versus 19.09(8.12), p = 0.001) and on (1)H-MRS increased myo-inositol/creatine ratios (mI/Cr, a marker of cerebral inflammation) in the basal ganglia (ratio of 0.71(0.22) versus 0.55(0.23), p = 0.03), compared to subjects with HIVmono. On PET imaging, no difference in (11)C-PK11195 binding potential (BP) was observed between study groups (p>0.10 all cerebral locations), however lower BPs were associated with combination antiretroviral therapy (cART) use in the parietal (p = 0.01) and frontal (p = 0.03) cerebral locations.
Discussion: Poorer cognitive performance and disturbance of cerebral metabolites are observed in subjects with aHC,V compared to subjects with HIVmono. Higher (11)C-PK11195 BP was not observed in subjects with aHCV, but was observed in subjects not on cART.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Tozzi V, Balestra P, Serraino D, Bellagamba R, Corpolongo A, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses. 2005;21:706–713.
- Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, et al. Evidence for a cerebral effect of the hepatitis C virus. Lancet. 2001;358:38–39.
- Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35:433–439.
- Tracey I, Carr CA, Guimaraes AR, Worth JL, Navia BA, et al. Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: A proton magnetic resonance spectroscopic study. Neurology. 1996;46:783–788.
- Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004;41:845–851.
- Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology. 2004;62:957–962.
- Richardson JL, Nowicki M, Danley K, Martin EM, Cohen MH, et al. Neuropsychological functioning in a cohort of HIV- and hepatitis C virus-infected women. Aids. 2005;19:1659–1667.
- Letendre SL, Cherner M, Ellis RJ, Marquie-Beck J, Gragg B, et al. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. Aids. 2005;19:S72–78.
- Murray J, Fishman SL, Ryan E, Eng FJ, Walewski JL, et al. Clinicopathologic correlates of hepatitis C virus in brain: a pilot study. J Neurovirol. 2008;14:17–27.
- Laskus T, Radkowski M, Bednarska A, Wilkinson J, Adair D, et al. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol. 2002;76:10064–10068.
- Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol. 2004;78:5170–5183.
- Gonzalez-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci. 1999;22:219–240.
- Forton DM, Allsop JM, Cox IJ, Hamilton G, Wesnes K, et al. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. Aids. 2005;19:S53–63.
- Rojas S, Martin A, Arranz MJ, Pareto D, Purroy J, et al. Imaging brain inflammation with [(11)C]PK11195 by PET and induction of the peripheral-type benzodiazepine receptor after transient focal ischemia in rats. J Cereb Blood Flow Metab. 2007;27:1975–1986.
- Shah F, Hume SP, Pike VW, Ashworth S, McDermott J. Synthesis of the enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl Med Biol. 1994;21:573–581.
- Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123 (Pt. 2000;11):2321–2337.
- Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, et al. Imaging microglial activation in Huntington’s disease. Brain Res Bull. 2007;72:148–151.
- Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. 2006;21:404–412.
- Cagnin A, Taylor-Robinson SD, Forton DM, Banati RB. In vivo imaging of cerebral “peripheral benzodiazepine binding sites” in patients with hepatic encephalopathy. Gut. 2006;55:547–553.
- Grover VPB PN, Koh SB, Wylezinska M, et al. Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation. J Viral Hepatol. 2012;19:89–96.
- Hammoud DA, Endres CJ, Chander AR, Guilarte TR, Wong DF, et al. Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neurovirol. 2005;11:346–355.
- Wiley CA, Lopresti BJ, Becker JT, Boada F, Lopez OL, et al. Positron emission tomography imaging of peripheral benzodiazepine receptor binding in human immunodeficiency virus-infected subjects with and without cognitive impairment. J Neurovirol. 2006;12:262–271.
- Browne R, Asboe D, Gilleece Y, Atkins M, Mandalia S, et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? Sex Transm Infect. 2004;80:326–327.
- Ghosn J, Pierre-Francois S, Thibault V, Duvivier C, Tubiana R, et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med. 2004;5:303–306.
- Winston A, Garvey L, Scotney E, Yerrakalva D, Allsop JM, et al. Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals? J Viral Hepat. 2010;17:419–426.
- Cysique LA, Maruff P, Darby D, Brew BJ. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol. 2006;21:185–194.
- Winston A, Duncombe C, Li PC, Gill JM, Kerr SJ, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis. 2010;50:920–929.
- Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA. 2001;12:141–152.
- Kanowski M, Kaufmann J, Braun J, Bernarding J, Tempelmann C. Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES. Magn Reson Med. 2004;51:904–912.
- Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153–158.
- Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med. 2007;48:158–167.
- Morgello S, Estanislao L, Ryan E, Gerits P, Simpson D, et al. Effects of hepatic function and hepatitis C virus on the nervous system assessment of advanced-stage HIV-infected individuals. Aids. 2005;19:S116–122.
- Ridderinkhof KR, Ullsperger M, Crone EA, Nieuwenhuis S. The role of the medial frontal cortex in cognitive control. Science. 2004;306:443–447.
- Melrose RJ, Tinaz S, Castelo JM, Courtney MG, Stern CE. Compromised fronto-striatal functioning in HIV: an fMRI investigation of semantic event sequencing. Behav Brain Res. 2008;188:337–347.
- Haussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol. 2000;32:1035–1038.
- Forton DM, Hamilton G, Allsop JM, Grover VP, Wesnes K, et al. Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study. J Hepatol. 2008;49:316–322.
- Kim SJ, Kim IJ, Kim YK, Lee TH, Lee JS, Jun S, et al. Probabilistic anatomic mapping of cerebral blood flow distribution of the middle cerebral artery. J Nucl Med. 2008;49:39–43.
- Chaudhuri A, Behan PO. Fatigue in neurological disorders. Lancet. 2004;363:978–988.
- Malm TM, Koistinaho M, Parepalo M, Vatanen T, Ooka A, et al. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis. 2005;18:134–142.
- Brown AK, Fujita M, Fujimura Y, Liow JS, Stabin M, et al. Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: a PET radioligand to image inflammation. J Nucl Med. 2007;48:2072–2079.
- Endres CJ, Pomper MG, James M, Uzuner O, Hammoud DA, et al. Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med. 2009;50:1276–1282.
- Venneti S, Wang G, Nguyen J, Wiley CA. The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders. J Neuropathol Exp Neurol. 2008;67:1001–1010.
- Christensen JD, Kaufman MJ, Levin JM, Mendelson JH, Holman BL, et al. Abnormal cerebral metabolism in polydrug abusers during early withdrawal: a 31P MR spectroscopy study. Magn Reson Med. 1996;35:658–663.
- Vogel M, Dominguez S, Bhagani S, Azwa A, Page E, et al. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort. Antivir Ther. 2010;15:267–279.
Source: PubMed